OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic
The overarching purpose of this retrospective, non-interventional study is to describe the features of COVID-19 infection in cancer patients, investigate its severity in this population and evaluate long-term outcomes.
| Imperial PI | Dr David Pinato |
| Trial Sponsor | Imperial College London |
| Study type | Observational |
| Study status | Retrospective analysis |
Total participants to date |
Database of 1520 patients analysed |
Since study inception on March 24th, the first interim analysis of a database of 204 cancer patients with Covid-19 has been completed, and the study opened to 8 centres in UK, Spain and Italy, with another 6 joining later.
Two manuscripts have been published to date:
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.
Cancer Discovery
A large Imperial-led study has revealed valuable insights into the impact and risk factors for cancer patients with COVID-19.The findings, from almost 900 cancer patients diagnosed with SARS-CoV-2 infection in the UK, Spain, Italy and Germany, highlight a number of key clinical insights. Read More…
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe
Cancers
This paper describes outcomes in 204 cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. Read More…
Find out more about the the study, centres and latest news, here.